Dana-Farber to Transition Breast Oncology in Boston
Starting October 19, breast oncology services will move to the Beth Israel Deaconess Medical Center partnership.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you believe hospital system mergers in your community typically lead to better patient care?
Beginning October 19, 2026, the Dana-Farber Cancer Institute will shift its breast oncology services from Brigham and Women's Hospital to Beth Israel Deaconess Medical Center. This change reflects the new collaborative model for outpatient and surgical care in Boston.
Why it matters
This move marks a significant realignment of cancer care infrastructure in the region as Dana-Farber prepares to conclude its long-standing partnership with Brigham and Women's Hospital. It also establishes the framework for future joint operations between Dana-Farber and Beth Israel Deaconess.
The transition involves a surgical division currently staffed by nine surgeons, two of whom previously practiced at Brigham and Women's. Plans are also underway for a future $1.68 billion, 300-bed cancer hospital.
The players
Dana-Farber Cancer Institute
This is a comprehensive cancer treatment and research institution based in Boston that is affiliated with Harvard Medical School.
Beth Israel Deaconess Medical Center
This is a major Boston-based teaching hospital that serves as a primary clinical partner for the Harvard Medical School system.
Dr. Elizabeth Mittendorf
She is a prominent surgical oncologist who joined the medical staff at Beth Israel Deaconess Medical Center in 2025.
Brigham and Women's Hospital
This is a leading teaching hospital in Boston and part of the Mass General Brigham healthcare network.
Mass General Brigham
This is a large integrated healthcare system in Massachusetts that operates several major hospitals and research institutes.
The details
Under the new arrangement, Dana-Farber will manage outpatient breast oncology services, while breast cancer surgeries will be performed at Beth Israel Deaconess Medical Center. These surgeons will integrate with broader teams including radiation, pathology, and reconstructive surgery.
Timeline
The transition of breast oncology services begins on October 19, 2026.
Dana-Farber and Beth Israel Deaconess established their partnership in 2023.
Dr. Elizabeth Mittendorf joined the Beth Israel Deaconess team in 2025.
The partnership between Dana-Farber and Brigham and Women's Hospital will end in 2028.
A new 300-bed cancer hospital is scheduled to open in 2031.
Health Landscape
This transition is part of a larger consolidation and realignment of specialty cancer care in the Boston area. It represents a significant strategic shift as major hospital networks compete for market dominance through substantial capital investments.
Patients receiving breast oncology care may need to navigate new locations for outpatient consultations and surgical procedures as services consolidate. This change aims to streamline access to multidisciplinary teams, though it requires patients to adjust to the new institutional workflow.
The takeaway
Patients should confirm their upcoming appointments and surgical sites to ensure continuity of care during this transition period. Integrating oncology services can lead to more collaborative care, but patients should remain proactive in communicating with their providers regarding location changes.
What happens next
The partnership between Dana-Farber and Brigham and Women's Hospital is scheduled to conclude in 2028, followed by the planned opening of a new 300-bed cancer hospital in 2031.
Further reading
For more information on regional oncology changes, visit the Boston Cancer section.
Source note: This article includes information reported by The Boston Globe.
Live Poll
Do you believe hospital system mergers in your community typically lead to better patient care?
